On 16 January 2025, Johnson & Johnson (J&J) announced that Health Canada has approved its Rybrevant® (amivantamab for injection) in combination with standard of care chemotherapy (carboplatin and pemetrexed) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with osimertinib.
This follows US FDA approval for the same combination therapy and indication in September 2024, and a positive recommendation by the EMA in July 2024. In December 2024, the EMA approved Rybrevant® in combination with Lazcluze® (lazertinib) for the same indication.